D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global registrational trials.
The Shanghai-based biotech plans to evaluate the drug …
Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.
Patients who were given Roche’s experimental breast cancer pill directly after having surgery were 30% less likely to have invasive disease recurrence than those who
After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.
A biotech with plans to make an oral drug that has the same target as Humira, formerly the world’s top-selling medicine, has raised $47.5 million
Since Takeda paid billions for Nimbus Therapeutics’ program in 2022, TYK2 has been one of immunology’s hottest targets. But it’s also crowded, with biotechs herding
D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global registrational trials.
The Shanghai-based biotech plans to evaluate the drug …